{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"24","value":"13"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"15","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Death in a patient who had not relapsed after transplant is defined as transplant-related mortality event.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tacro-MTX/Sirolimus GVHD Prophylaxis","id":"OG000","title":"Experimental"},{"description":"Tacro-MTX GVHD Prophylaxis","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"2 ineligible patients on experimental arm excluded from analysis.","reportingStatus":"POSTED","timeFrame":"100 days","title":"Estimated Transplant Related Mortality Percentage","type":"SECONDARY","unitOfMeasure":"percentage of participants"}